<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>To better define the incidence and causes of canine <z:hpo ids='HP_0001876'>pancytopenia</z:hpo>, we retrospectively evaluated the results of complete blood counts submitted to the University of Minnesota Veterinary Teaching Hospital during a 1-year period </plain></SENT>
<SENT sid="1" pm="."><plain><z:hpo ids='HP_0001876'>Pancytopenia</z:hpo> was defined as packed cell volume &lt; 36%, total leukocyte count &lt; 6,000/microliter or total segmented neutrophil count &lt; 3,000/microliter, and platelet count &lt; 200,000/microliter </plain></SENT>
<SENT sid="2" pm="."><plain>Of 4,560 complete blood counts, 110 (2.4%) samples from 51 dogs met the criteria for <z:hpo ids='HP_0001876'>pancytopenia</z:hpo> </plain></SENT>
<SENT sid="3" pm="."><plain>Eleven different disease processes were identified </plain></SENT>
<SENT sid="4" pm="."><plain>These included chemotherapy-associated <z:hpo ids='HP_0001876'>pancytopenia</z:hpo> (n=22), <z:e sem="disease" ids="C0205882" disease_type="Disease or Syndrome" abbrv="">parvovirus infection</z:e> (n=5), malignant <z:mpath ids='MPATH_146,MPATH_652'>histiocytosis</z:mpath> (n=5), idiopathic <z:hpo ids='HP_0001915'>aplastic anemia</z:hpo> (n=3), <z:hpo ids='HP_0100806'>sepsis</z:hpo> (n=3), <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> (n=3), immune-mediated <z:e sem="disease" ids="C0018939" disease_type="Disease or Syndrome" abbrv="">hematologic disease</z:e> (n=3), lymphoblastic <z:hpo ids='HP_0001909'>leukemia</z:hpo> (n=2), <z:e sem="disease" ids="C0085399,C0878686" disease_type="Disease or Syndrome" abbrv="">ehrlichiosis</z:e> (n=2), <z:chebi fb="0" ids="50114">estrogen</z:chebi> toxicity (n=2), and <z:hpo ids='HP_0006775'>multiple myeloma</z:hpo> (n=1) </plain></SENT>
<SENT sid="5" pm="."><plain>Malignant <z:mpath ids='MPATH_146,MPATH_652'>histiocytosis</z:mpath> and idiopathic <z:hpo ids='HP_0001915'>aplastic anemia</z:hpo> occurred more frequently than was expected </plain></SENT>
<SENT sid="6" pm="."><plain>Doxoruicin was the chemotherapeutic agent associated with <z:hpo ids='HP_0001876'>pancytopenia</z:hpo> </plain></SENT>
<SENT sid="7" pm="."><plain>Hematologic recovery and patient survival time varied with the cause of <z:hpo ids='HP_0001876'>pancytopenia</z:hpo>; therefore, a specific diagnosis was essential for establishing prognosis </plain></SENT>
<SENT sid="8" pm="."><plain>Differentiation among causes of <z:hpo ids='HP_0001876'>pancytopenia</z:hpo> requires a systemic approach that includes elimination of infectious and drug-induced causes, and examination of bone marrow <z:hpo ids='HP_0002835'>aspiration</z:hpo> and core biopsy specimens </plain></SENT>
</text></document>